Herpetic WhitlowMANAGEMENT

DERMATOLOGY PRESENTATIONS · 12 SECTIONS

⚲

605 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Allergic contact dermatitis Bullous Pemphigoid Cutaneous Abscess DRESS syndrome Eczema Herpeticum Erysipelas Erythema multiforme Henoch-Schönlein purpura Herpes Zoster (Shingles)Herpetic Whitlow Hidradenitis suppurativa Paronychia Pediculosis (Lice)Pemphigus Vulgaris Pilonidal Abscess Pressure injury Psoriasis (acute flare)Psoriasis Flare Staphylococcal Scalded Skin Syndrome Stevens-Johnson Syndrome (SJS)Toxic Epidermal Necrolysis (TEN)Urticaria (acute)Warfarin-induced Skin Necrosis

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp45

Immediate priorities

›Recognition of a limb-threatening mimic

›Pyogenic flexor tenosynovitis must be excluded first

›Kanavel sign 1: fusiform swelling of the entire digit

›Kanavel sign 2: digit held in flexed posture

›Kanavel sign 3: tenderness along flexor tendon sheath

›Kanavel sign 4: pain with passive extension

›If any Kanavel sign present, emergent hand surgery consultation

›Do not delay for imaging

›Surgical emergency with risk of permanent tendon damage

›Critical clinical rule: do NOT incise and drain herpetic whitlow

›Incision converts a self-limiting viral infection to an open wound

›Risk of secondary bacterial superinfection

›Risk of prolonged healing and scarring

›65% of pediatric herpetic whitlow cases initially misdiagnosed as bacterial felon

›This drives inappropriate surgical referrals

›Immunocompromised host threat assessment

›HIV, transplant, chemotherapy, high-dose steroids

›Risk of disseminated HSV infection

›Risk of chronic non-healing ulcers

›Risk of acyclovir-resistant HSV strains

›Escalate to IV antiviral therapy if systemic features present

Key decision points

›Distinguishing herpetic whitlow from bacterial felon

›Herpetic whitlow features

›Grouped vesicles on erythematous base

›Clear to serosanguinous fluid, not frankly purulent

›Tender but not tense or fluctuant

02History/hx55

Presenting symptoms

›Core symptom complex

›Painful, swollen distal digit with grouped vesicles

›Volar aspect of distal phalanx most common

›Index finger and thumb most frequently affected

›Prodrome preceding vesicle formation by up to 72 hours

›Tingling or burning at affected digit

›Itching or paresthesias

›Vesicle characteristics

›Grouped appearance, may coalesce into honeycomb pattern

›Fluid clear to serosanguinous, not purulent

›Duration context

›Primary infection: 14-21 days in immunocompetent hosts

›Primary infection in healthcare workers: up to 21-28 days

Exposure and inoculation history

›Mechanism of inoculation

›Children: thumb or finger sucking with concurrent herpetic gingivostomatitis

›HSV-1 autoinoculation most common mechanism in pediatric cases

›Healthcare workers: contact with patient oral secretions or lesions

›Pre-universal precautions: dentists, nurses, respiratory therapists at high risk

›Adults: contact with active oral herpes (HSV-1) or genital herpes (HSV-2)

›Autoinoculation via broken skin or cuticle

›Nail biting or skin picking at periungual area

›Recurrence history

›Prior episodes on the same digit

›HSV-2 whitlow recurs more frequently than HSV-1

›Recurrence rate approximately 23% in pediatric cases

›Prodromal triggers for recurrence

03Physical Exam/exam41

Digit inspection

›Vesicle morphology assessment

›Grouped vesicles on an erythematous base

›Volar or lateral aspect of distal phalanx

›May coalesce into honeycomb appearance

›Fluid character

›Clear to serosanguinous (not frankly purulent)

›Seropurulent appearance can occur with secondary infection

›Stage of lesion

›Prodromal: erythema and edema without vesicles

›Vesicular: intact grouped vesicles

›Ulcerative: ruptured vesicles with shallow erosions

›Crusting: healing phase, still infectious until fully crusted

Palpation and functional exam

›Tissue consistency

›Tender but not tense or fluctuant

›Tense fluctuance suggests bacterial felon, not herpetic whitlow

›Swelling confined to distal phalanx

›Extension beyond DIP joint raises concern for tenosynovitis

›Kanavel signs for flexor tenosynovitis exclusion

›Fusiform swelling of entire digit

›Digit held in flexed posture at rest

›Uniform tenderness along flexor tendon sheath

›Pain with passive extension of digit

›Nail exam

›Subungual vesicles

›Periungual involvement

›Nail plate integrity

04Differential Diagnosis/ddx41

Must-not-miss diagnoses

›Pyogenic flexor tenosynovitis

›ICD-10: M65.04 (Other synovitis and tenosynovitis, hand)

›Kanavel signs distinguish from whitlow

›Surgical emergency; irreversible tendon damage if delayed

›Bacterial felon

›ICD-10: L03.011 (Cellulitis of right finger)

›Tense, fluctuant pulp space abscess

›Frank purulence distinguishes from herpetic vesicles

›Requires incision and drainage, unlike herpetic whitlow

Common mimics

›Acute bacterial paronychia

›ICD-10: L03.041 (Acute paronychia)

›Infection of nail fold with purulent drainage

›May coexist with herpetic whitlow

›No grouped vesicles on erythematous base

›Bacterial cellulitis of the digit

›ICD-10: L03.011

›Diffuse erythema without discrete vesicular grouping

›No prodromal paresthesias

›Contact dermatitis

›ICD-10: L23.9

›Pruritic rather than painful

›No grouped vesicles on erythematous base

›History of irritant or allergen exposure

Less common diagnoses

›Blistering dactylitis (streptococcal)

›ICD-10: L08.9

05Laboratory Tests/lt48

Confirmatory virologic testing

›HSV PCR (NAAT) from lesion base

›Highest sensitivity for HSV diagnosis: 96.7-100%

›Specimen collection: vigorously swab base of unroofed vesicle

›Unroofing vesicle with sterile needle maximizes specimen yield

›Distinguishes HSV-1 from HSV-2

›HSV-2 associated with higher recurrence frequency

›IDSA/ASM 2024 guidelines: PCR preferred over viral culture for HSV skin/mucosal infections

›IDSA Level B recommendation

›Viral culture

›Sensitivity 30-70%, lower than PCR

›Useful when antiviral susceptibility testing is needed

›Acyclovir resistance in immunocompromised hosts

›Transport swab in viral transport medium

›Yield declines rapidly after vesicle rupture

Rapid and point-of-care testing

›Direct fluorescent antibody (DFA) testing

›Less sensitive than PCR but provides same-day results

›Distinguishes HSV-1, HSV-2, and VZV

›Requires viable cells from freshly unroofed vesicle

›Tzanck smear

›Rapid bedside test: multinucleated giant cells on Giemsa stain

›Low sensitivity; non-specific for HSV vs. VZV

›Not recommended as sole confirmatory test

›Clinical diagnosis

›Sufficient in classic presentations in immunocompetent hosts

›Confirmatory testing recommended when diagnosis uncertain

›Confirmatory testing mandatory in immunocompromised patients

06Diagnostic Tests/dt44

Scoring Systems

›No validated scoring system specific to herpetic whitlow

›Clinical diagnosis remains the standard approach

›Grouped vesicles on erythematous base on the distal digit

›Tender but non-fluctuant on palpation

›Kanavel criteria used to exclude flexor tenosynovitis

›Four classic signs evaluated sequentially

›Positive predictive value increases with number of signs present

›Risk stratification framework

›Low-risk: immunocompetent, classic presentation, no alarm features

›Outpatient management appropriate

›High-risk: immunocompromised, systemic toxicity, Kanavel signs

›Requires urgent evaluation and potential admission

MRI

›MRI of digit or hand

›Not indicated in typical uncomplicated herpetic whitlow

›Diagnosis is clinical with optional PCR confirmation

›Indications for MRI consideration

›Suspected deep space infection

›Concern for osteomyelitis in chronic or recurrent cases

›Atypical presentation with diagnostic uncertainty

›MRI findings in deep space infections

›T2 hyperintensity along tendon sheath in tenosynovitis

›Bone marrow edema in osteomyelitis

›Fluid collections in deep space abscess

›CT of the hand

›No role in typical herpetic whitlow presentation

07Disposition/dispo32

Discharge criteria

›Standard outpatient discharge criteria

›Immunocompetent host with classic presentation

›No systemic toxicity (afebrile or low-grade fever only)

›No Kanavel signs

›No rapidly spreading cellulitis

›Diagnosis confirmed or highly probable clinically

›Patient able to tolerate oral antivirals

›Reliable follow-up arranged within 7-10 days

Admission criteria

›Indications for inpatient admission

›Immunocompromised host with severe or disseminated HSV

›IV acyclovir therapy required

›Infectious disease consultation recommended

›Secondary bacterial infection requiring IV antibiotics

›Cellulitis with systemic toxicity

›Failure of oral antibiotic trial

›Suspected pyogenic flexor tenosynovitis

›Emergent hand surgery consultation and operative management

›Inability to care for wound or take oral medications

Surgical consultation triggers

›Hand surgery consultation indications

›Any Kanavel sign present

›Do not await all four signs to consult

›Early consultation improves tendon salvage outcomes

›Confirmed bacterial abscess coexisting with herpetic whitlow

›Requires drainage of the bacterial component

›Surgery is contraindicated for herpetic whitlow itself

08Treatment/t78

Conservative management (all cases)

›Wound care and supportive measures

›Elevation of affected digit

›Reduces swelling and discomfort

›Dry, non-adherent dressing

›Prevents autoinoculation to other sites

›Prevents transmission to contacts

›Analgesics for pain control

›Acetaminophen 325-650 mg PO every 4-6 hours as needed

›NSAIDs: ibuprofen 400-600 mg PO every 6-8 hours with food

›Nerve block consideration for severe pain

›Digital block using 1-2% lidocaine without epinephrine

›Contraindicated interventions

›Incision and drainage strictly avoided

›IDSA 2014 guidelines: HSV whitlow is an aseptic process

›I&D introduces bacterial infection and worsens outcomes

›Topical antibiotics are not beneficial for uncomplicated viral infection

›Avoid unnecessary systemic antibiotics unless bacterial superinfection documented

Antiviral therapy

›Primary infection treatment

›Valacyclovir (preferred for dosing convenience)

›1 g PO twice daily for 7-10 days

›Renal dose adjustment required if eGFR < 50 mL/min

›Best initiated during prodrome or within 48-72 hours of onset

›Acyclovir

›400 mg PO 5 times per day for 7-10 days

›Renal dose adjustment required

›Adequate hydration essential: minimum 2 L/day to prevent crystalline nephropathy

›Famciclovir

›250 mg PO three times daily for 7-10 days

›Renal dose adjustment required if eGFR < 40 mL/min

›Recurrent infection treatment

›Valacyclovir

›500 mg PO twice daily for 5 days

›Initiate at first sign of prodrome for maximum benefit

›Acyclovir

›200 mg PO 5 times per day for 5 days

›Alternative: 800 mg PO twice daily initiated during prodrome may abort attack

›Famciclovir

›125 mg PO twice daily for 5 days

Suppressive antiviral therapy

›Indications for long-term suppression

›Six or more recurrences per year

›Reduces recurrence frequency by approximately 70-80%

›Significant occupational or personal impact from recurrences

›Suppressive regimens

›Valacyclovir

›500 mg PO once daily (patients with < 10 recurrences per year)

›1 g PO once daily (patients with >= 10 recurrences per year)

›Renal dose adjustment required

›Acyclovir

›400 mg PO twice daily

›Renal dose adjustment required

›Annual reassessment to determine if suppression still required

Immunocompromised host treatment

›Severe or disseminated HSV in immunocompromised patients

›IV acyclovir

›5 mg/kg IV every 8 hours for 7-10 days

›Infuse over at least 1 hour to reduce nephrotoxicity risk

›Aggressive IV hydration: 500 mL normal saline before and during infusion

›Renal function monitoring every 24-48 hours

›Reduce dose for eGFR < 50 mL/min

›Acyclovir-resistant HSV

›Suspected in immunocompromised patients failing acyclovir therapy

›Viral culture with susceptibility testing required

›Foscarnet

›40 mg/kg IV every 8 hours for 14-21 days

›Nephrotoxic: aggressive hydration and electrolyte monitoring required

›Monitor serum creatinine, calcium, phosphate, magnesium daily

›Cidofovir (second-line alternative)

›5 mg/kg IV once weekly for 2 weeks

›Requires probenecid and IV hydration pretreatment

›Significant nephrotoxicity risk

Bacterial superinfection treatment

›Empiric antibiotic selection when superinfection confirmed

›Mild to moderate: oral therapy

›Dicloxacillin 500 mg PO four times daily for 5-7 days

›Cephalexin 500 mg PO four times daily for 5-7 days

›If MRSA suspected: trimethoprim-sulfamethoxazole DS one tablet PO twice daily

›Severe or systemic: IV therapy

›Nafcillin 1-2 g IV every 4 hours

›Vancomycin 15-20 mg/kg IV every 8-12 hours if MRSA suspected

›Target AUC/MIC 400-600 or trough 15-20 mcg/mL

09Special Populations/sp53

Pregnancy

›HSV infection in pregnancy considerations

›Herpetic whitlow itself does not directly increase obstetric risk

›Primary infection: monitor for rare systemic dissemination

›Active lesions are infectious: strict hand hygiene mandatory

›Antiviral safety in pregnancy

›Acyclovir: FDA Category B; extensive safety data support use in pregnancy

›400 mg PO 5 times per day for primary infection

›Preferred agent due to longest safety record

›Valacyclovir: FDA Category B; used in second and third trimester for genital HSV

›Data for whitlow specifically limited but extrapolated from genital HSV data

›Famciclovir: limited pregnancy safety data; avoid in first trimester if alternatives available

›Neonatal transmission risk

›Active whitlow lesions in a postpartum caregiver represent neonatal exposure risk

›Cover all active lesions and practice strict hand hygiene around neonates

›Neonatal HSV has mortality of 25-60% without treatment

Geriatric

›Age-related considerations

›Renal function decline affects antiviral dosing

›Calculate eGFR before prescribing acyclovir, valacyclovir, or famciclovir

›Acyclovir dose reduction: eGFR 10-25 mL/min: 200 mg PO three times daily

›Valacyclovir dose reduction: eGFR 10-29 mL/min: 500 mg PO every 24 hours

›Increased risk of dehydration with acyclovir

›Nephrotoxicity risk higher in elderly

›Ensure adequate fluid intake counseling

›Presentation may be atypical

›Older adults may have less pronounced vesiculation

›Pain may be described as burning or dysesthesia rather than classic prodrome

10Background/b67

Epidemiology

›Incidence and prevalence

›Herpetic whitlow represents approximately 2.4 per 100,000 population per year

›Exact incidence difficult to establish due to frequent misdiagnosis

›Bimodal age distribution

›First peak: children under 10 years (HSV-1 autoinoculation)

›Second peak: adults 20-40 years (HSV-1 and HSV-2 from oral or genital contact)

›Sex distribution: slight female predominance in adult cases

›HSV type distribution

›Children: predominantly HSV-1 (autoinoculation from oral HSV)

›Adults: HSV-1 and HSV-2 roughly equal, varies by sexual practices

›HSV-2 associated with more frequent recurrences

›Occupational risk

›Healthcare workers historically at highest risk before universal precautions

›Dentists, dental hygienists, nurses, respiratory therapists

›Widespread glove use has significantly reduced occupational incidence

›Current occupational risk exists when PPE compliance is poor

›ICD-10 coding

›B00.89: Other herpes simplex infections (herpetic whitlow)

Pathophysiology

›Viral biology

›Causative agents: herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2)

›Enveloped double-stranded DNA virus

›Both types can cause whitlow; HSV-1 predominates in children

›Inoculation mechanism

›Direct inoculation of virus into disrupted skin or mucosa of the digit

›Broken cuticle, hangnail, skin fissure, or eczematous skin provides entry

›Minimum infective dose very low; even microscopic breaks in skin are sufficient

›Disease course

›Primary infection

›Incubation: 2-20 days after inoculation

›Prodrome: tingling, burning, paresthesia preceding vesicles by up to 72 hours

›Vesicular phase: grouped vesicles on erythematous base

›Pustular or coalescent phase: vesicles may become turbid or honeycomb

›Ulcerative phase: vesicle rupture with shallow erosions

›Crusting and resolution: 7-10 days to crust, full healing 14-21 days

›Viral latency and recurrence

›Virus travels retrograde along sensory nerve axons to dorsal root ganglion

›Establishes latency in cervical or thoracic dorsal root ganglion

›Reactivation triggered by stress, fever, UV exposure, immunosuppression

›Recurrent episodes shorter and less severe than primary

Therapeutic Considerations

›Antiviral mechanism and rationale

›Acyclovir, valacyclovir, famciclovir: nucleoside analogues

›Activated by HSV thymidine kinase (viral-specific enzyme)

›Inhibit viral DNA polymerase, preventing replication

›Selective for HSV-infected cells; minimal toxicity to normal cells

›Valacyclovir: prodrug of acyclovir

›Better oral bioavailability than acyclovir (55% vs 15-30%)

›Fewer daily doses required

›Famciclovir: prodrug of penciclovir

›Bioavailability 77%

›Long intracellular half-life allows twice or three times daily dosing

›Treatment timing evidence base

›Greatest benefit when initiated during prodrome or within 48-72 hours of lesion onset

›Reduces duration of viral shedding

›May reduce lesion duration by 1-2 days

›Beyond 72 hours: antivirals have diminishing impact on episode duration

›Still reasonable to initiate given safety profile and suppression of shedding

›Acyclovir resistance

›Occurs in approximately 3-5% of immunocompromised patients on chronic acyclovir

›Mechanism: loss or mutation of viral thymidine kinase

›Resistance rare in immunocompetent hosts

›Clinical features: failure to heal on standard acyclovir after 7-10 days

›Foscarnet is treatment of choice: acts independently of thymidine kinase

›Hydration and renal protection

›Acyclovir can precipitate in renal tubules causing crystalline nephropathy

›Risk highest with IV formulation, dehydration, and pre-existing renal impairment

›Oral acyclovir: encourage minimum 2 L of fluid daily

›IV acyclovir: administer over 1 hour with concurrent hydration

11Patient Discharge Instructions/pdi42

copy discharge instructions

›Diagnosis and what to expect

›Your finger is infected with herpes simplex virus (herpetic whitlow)

›This is a viral infection that causes painful blisters on the finger

›The infection will heal on its own in 2-3 weeks in most people

›Antiviral medication may help shorten the duration if started early

›Do NOT squeeze, pop, or cut open the blisters

›Opening the blisters increases the risk of bacterial infection

›This is the most common cause of complications from this condition

›Medications

›Take your antiviral medication exactly as prescribed

›Complete the full course even if the blisters start to heal

›Take with plenty of water (at least 8 glasses per day)

›For pain, you may use

›Acetaminophen (Tylenol) 325-500 mg every 4-6 hours as needed

›Ibuprofen (Advil, Motrin) 400-600 mg every 6-8 hours with food as needed

›Do not use antibiotics unless specifically prescribed for you

›Wound care

›Keep the finger clean and dry

›Cover with a clean, non-adhesive bandage

›Change the dressing once or twice daily or when wet

›Elevate your hand above heart level to reduce swelling

›Contagion and infection control

›The virus is contagious until all blisters are fully crusted over

›This typically takes 7-10 days

›Avoid direct skin contact between your affected finger and other people

›Especially avoid contact with newborns and immunocompromised individuals

›Avoid touching your eyes with the affected finger (risk of eye infection)

12References/r59

Guidelines and key sources

›IDSA Practice Guidelines for Skin and Soft Tissue Infections 2014

›Stevens DL, Bisno AL, Chambers HF, et al.

›Clinical Infectious Diseases 2014

›doi: 10.1093/cid/ciu296

›Defines herpetic whitlow as an aseptic process; I&D contraindicated

›IDSA/ASM Guide to Utilization of Microbiology Laboratory 2024

›Miller JM, Binnicker MJ, Campbell S, et al.

›Clinical Infectious Diseases 2024

›doi: 10.1093/cid/ciae104

›PCR preferred over viral culture for HSV skin and mucosal infections

›IDSA Opportunistic Infections in HIV Guidelines 2025

›Benson C, Brooks J, Dhanireddy S, et al.

›IDSA and Office of AIDS Research Advisory Council 2025

›Foscarnet recommended for acyclovir-resistant HSV in immunocompromised patients

Primary literature

›Gill MJ, Arlette J, Tyrrell DL, Buchan KA (1988)

›Herpes Simplex Virus Infection of the Hand: Clinical Features and Management

›American Journal of Medicine 1988

›PMID: 3407676

›Documents antiviral dosing and efficacy for HSV hand infections

›Salerno N, Doolan JJ (2022)

›An Unusual Pediatric Manifestation of the Herpes Simplex Virus

›Journal of the American Podiatric Medical Association 2022

›PMID: 35994408

›Describes pediatric presentation, misdiagnosis rates, and recurrence data

›Szinnai G, Schaad UB, Heininger U (2001)

›Multiple Herpetic Whitlow Lesions in a 4-Year-Old Girl: Case Report and Review

Learn More: Herpetic Whitlow→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.